摘要
目的:比较健择联合奥沙利铂双周化疗方案和健择单药每周方案治疗胰腺癌的疗效及不良反应。方法:选择我科2003年11月至2005年1月胰腺癌患者30例,采用健择联合奥沙利铂双周化疗方案(设为A组:健择1000mg/m2d1,奥沙利铂100mg/m2d2,每隔14天进行1个周期)进行治疗;随机选择同时期使用健择单药方案(设为B组:健择1000mg/m2单药,每周1次,连续3周,随后休息1周为1个周期)化疗的胰腺癌患者30例做对照,比较两方案治疗胰腺癌的疗效和不良反应的差异。结果:A组PR3例,SD21例,PD6例,1年生存率为16.7%(5/30)。B组PR1例,SD14例,PD15例,1年生存率为10.0%(3/30)。化疗的主要不良反应包括:恶心、呕吐,骨髓抑制和外周神经毒性。结论:健择加奥沙利铂双周化疗方案在抑制肿瘤发展、延长生存期方面略优于传统健择单药方案,而两者不良反应大体相当,推荐临床使用。
Objective： To compare the curative and adverse effects of gemcitabine or gemzar plus oxaliplatin （GEMOX） and gemcitabine alone in biweekly chemotherapeutic regimens in patients with advanced pancreatic cancer. Methods： Thirty patients with advanced pancreatic cancer were chosen during a period from November 2003 to January 2005 to receive the biweekly GEMOX regimen, i.e., gemcitabine 1000 mg/m^2 infusion on day 1 followed by oxaliplatin 100 mg/m^2 on day 2, with a cycle of every 2 weeks （group A）. At the same time, another 30 patients from the same time period were randomly chosen to receive gemcitabine alone, i.e., 1000 mg/m^2 infusion on day 1, 8 and 15, once a week, with a cycle of every 4 weeks （group B）. The difference between the curative and adverse effects of the two regimens was compared. Results： The response rate of patients in group A was as follows： partial remission （PR） occurred in 3/30 cases （10%）, no change （NC） in 21/30 （70%） and progression of disease （PD） in 6/30 （20%）. A 1-year survival time was found in 5 patients （16.67%）. The response of patients in group B was that PR was seen in 1/30 cases （3.33%）, NC in 14/30 （46.7%） and PD in 15/30 （50%）. Three patients remained alive after 1 year （10.0%）. The major adverse effects of chemotherapy were nausea, vomiting, myelosuppression and peripheral neurotoxicity. Conclusion： The biweekly combined chemotherapeutic regimen has a slight advantage over the single gemzar regimen when comparing the inhibition of disease progression and prolonging of the survival time. However, the adverse effects of the two treatments are almost the same, so the biweekly regimen is recommended for clinical application.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2007年第6期322-325,共4页
Chinese Journal of Clinical Oncology
关键词
胰腺癌
化疗
健择
奥沙利铂
Pancreatic cancer
Chemotherapy
Gemcitabine
Oxaliplatin
